Suyeon Kim

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

P. Miranda, W. Park, A. Baranauskaitė, 2016, Annals of the rheumatic diseases.

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

P. Miranda, J. Braun, W. Park, 2016, Annals of the rheumatic diseases.

Clinical development of CT-P10 and other biosimilar cancer therapeutics.

B. Coiffier, W. Kim, H. Kwon, 2017, Future oncology.

Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis

Y. Kang, Deok-Ryun Kim, S. Kim, 2018, BMC Infectious Diseases.

Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis

Y. Kang, S. Kim, Y. S. Kim, 2018, BMC Infectious Diseases.